DURECT (DRRX) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for DURECT
Is DURECT a buy right now? The alternative data says hold. This DRRX stock analysis is built on the 25+ alternative data signals AltIndex tracks on DURECT every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $1.91 with a $59M market cap.
The soft spots over the past 90 days: web traffic down 92.2% to 111 monthly visits. The rest of the signal set is holding steady, which keeps DRRX at a hold rather than a sell.
DRRX’s broader alt-data profile also covers headcount (73 employees, according to LinkedIn), X followers (362), and sentiment (100/100). Every signal links to its own page with full history, the DRRX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on DRRX is just below.
DURECT AI Stock Analysis
DURECT Corporation is a biopharmaceutical company known for its innovative drug delivery platforms and proprietary therapeutic programs. The company focuses on the development of pharmaceuticals to treat chronic and acute medical conditions.
Analysis generated September 1, 2026.
Recent DURECT Stock Alerts
|
DURECT | August 23 Insider Alert: ASEN R SCOTT is buying shares |
|
DURECT | July 29 Price is up by 258% in the last 24h. |
|
DURECT | July 23 Price is up by 7.3% in the last 24h. |
|
DURECT | July 18 Price is up by 7.5% in the last 24h. |
DURECT Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 111 | 92.2% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 73 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 2 | 0% | |
| Stocktwits Mentions | 0 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 8K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 362 | 0% |
About DURECT (DRRX)
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program.
| Price | $1.91 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $59M |
| Year Range | $2 – $2 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest DURECT News
View more →
Tuberculosis Clinical Trial Pipeline Shows Potential with Active Contributions from 28+ Key Companies | DelveInsightJuly 14 - GlobeNewswire |
|
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsightJune 25 - GlobeNewswire |
|
Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightJune 23 - GlobeNewswire |
|
 |
Alcohol-associated Liver Disease Market Gearing Up for Outstanding Expansion at a CAGR of 31.1% During the Forecast Period (2026-2036) | DelveInsightJune 9 - PRNewswire |
 |
Focal white matter lesions drive grey matter inflammation and synapse lossApril 21 - Nature.com |
See DURECT’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for DRRX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEDURECT Earnings & Financial Performance
View all earnings →DURECT Insider Trading Activity
View all →| ASEN R SCOTT filed to sell 2,672,529 shares at $0.0. Aug 22 '25 |
| ASEN R SCOTT filed to sell 2,666,612 shares at $0.0. Aug 21 '25 |
| ASEN R SCOTT filed to sell 970,000 shares at $0.0. Aug 20 '25 |
| Robertson Judith J. filed to sell 356,132 shares at $0.0. Aug 19 '22 |
| Robertson Judith J. filed to sell 346,720 shares at $0.0. Aug 18 '22 |
DURECT Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to DURECT
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Impact BioMedicalIBO |
$0.54 12.5% | $58M | 48 |
 |
MiNK TherapeuticsINKT |
$11.64 3.7% | $57M | 54 |
 |
eXoZymes Inc. - Common StockEXOZ |
$6.85 0.7% | $64M | 53 |
 |
Kezar Life SciencesKZR |
$7.29 1.0% | $54M | 36 |
 |
ImmutepIMMP |
$0.36 0.1% | $54M | 46 |
Explore DURECT Data
Frequently Asked Questions: DURECT (DRRX)
DURECT has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of DURECT (DRRX) stock is $1.91 with a market cap of $59M.
As of today, DURECT’s PE (Price to Earnings) ratio is —.
View the latest DURECT insider transactions to see recent buying and selling activity by company executives and directors.
Check the DURECT congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The DRRX stock price chart above shows DURECT’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full DURECT technical analysis for RSI, moving averages, and more.
See the stocks similar to DURECT section on this page for companies in the same industry ranked by market cap and AI Score.
